Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been given an average rating of “Moderate Buy” by the six research firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $11.80.

CMPX has been the topic of a number of research analyst reports. Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th.

Institutional Trading of Compass Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its position in Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after buying an additional 19,095 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Compass Therapeutics by 12.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after purchasing an additional 31,433 shares during the period. Barclays PLC grew its stake in Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after purchasing an additional 112,614 shares during the period. Renaissance Technologies LLC increased its holdings in Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after purchasing an additional 70,200 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Compass Therapeutics by 10.3% in the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after buying an additional 12,315 shares during the period. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock opened at $2.50 on Friday. The business’s 50 day simple moving average is $1.60 and its 200 day simple moving average is $1.47. The firm has a market cap of $343.98 million, a PE ratio of -6.76 and a beta of 0.92. Compass Therapeutics has a 52-week low of $0.76 and a 52-week high of $2.70.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, equities research analysts predict that Compass Therapeutics will post -0.35 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.